As development continues in the care and management of plaque psoriasis, new research is regularly published on systemic treatments for moderate to severe cases. Plaque psoriasis is the most common form of psoriasis.
The Cochrane Skin team is part of the Cochrane international independent network of healthcare providers, researchers, and patient advocates. Cochrane has recently published new evidence on different medicines taken by mouth or injected to treat plaque psoriasis. The latest review (published April 2021) led by Drs. Emilie Sbidian and Laurence Le Cleach includes over 150 studies with more than 50,000 participants and compares non‐biological systemic agents, small molecules, and biologics.
This evidence will inform doctor’s decision making and support the development of global guidelines to treat plaque psoriasis. In short, after 6 months of treatment biologics appear to work best in achieving clear skin in adults with moderate-to-severe psoriasis. Long-term studies are needed to see the harms and benefits of longer treatment. Use key messages from the plain language summary to advocate for treatment.